Lorlatinib in ALK-Rearranged Lung Cancer

Cancer Cell. 2021 Jan 11;39(1):25-27. doi: 10.1016/j.ccell.2020.12.017.

Abstract

Should lorlatinib be the standard first-line treatment in advanced ALK-rearranged lung cancer? In the New England Journal of Medicine, Shaw et al. present interim analysis results from CROWN, a randomized, phase 3 study comparing lorlatinib with crizotinib as initial therapy in patients with advanced ALK-rearranged NSCLC.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Aminopyridines
  • Anaplastic Lymphoma Kinase / genetics
  • Crizotinib / therapeutic use
  • Humans
  • Lactams
  • Lactams, Macrocyclic
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Pyrazoles

Substances

  • Aminopyridines
  • Lactams
  • Lactams, Macrocyclic
  • Pyrazoles
  • Crizotinib
  • Anaplastic Lymphoma Kinase
  • lorlatinib